Arrowhead Pharmaceuticals' (ARWR) ARO-INHBE gene-silencing drug combined with Zepbound doubles weight loss in obese diabetes patients, targeting dangerous visceral and liver fat more effectively.
Wave Life Sciences' WVE-007 demonstrates 9.4% visceral fat reduction with muscle preservation in Phase 1 trial, earning positive analyst ratings and buy recommendations.
Arrowhead Pharmaceuticals received FDA Breakthrough Therapy designation for plozasiran, a promising treatment aimed at lowering dangerously high triglyceride levels in adults with severe hypertriglyceridemia.
FDA approves Arrowhead Pharmaceuticals' Redemplo for familial chylomicronemia syndrome, a rare genetic disorder causing dangerously high blood fat levels.
Pharma giant Roche bought 89bio for up to $3.5B. The focus is pegozafermin, a promising drug for treating MASH (severe fatty liver disease). This deal positions Roche to transform care in metabolic diseases. Shares of 89bio surged 85% on Thursday.
Novartis partners with Arrowhead Pharmaceuticals for ARO-SNCA, an innovative RNAi therapy targeting alpha-synuclein for Parkinson's Disease. The deal includes a $200M upfront payment and up to $2B in potential milestones.
